Following two separate deals with Duality Biologics, BioNTech SE has inked another antibody-drug conjugate (ADC) collaboration with another Chinese firm, Suzhou Medilink Therapeutics Ltd., in a deal worth up to more than $1bn. At the center of the agreement is YL202, a HER3-targeting candidate, Medilink announced on 12 October.
Key Takeaways
-
In exchange for global rights to YL202, BioNTech will pay Medilink $70m upfront, as well as development, regulatory and commercial milestone payments that could take total deal value to $1bn-plus.
-
HER3-targeting YL202 uses the TMALIN ADC platform, which is effective regardless of antibody endocytosis ability
The collaboration marks Medilink's first major alliance with a leading international partner, which has put in the spotlight the Chinese biotech’s novel ADC platform
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?